General MedicationsORALGeneric

CIPRO XR

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

Standard Dose

425.2MG;EQ 574.9MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview CIPRO XR is listed in Drugs@FDA under application 021473 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE Form and strength TABLET, EXTENDED RELEASE;ORAL - 425.2MG;EQ 574.9MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor BAYER HLTHCARE Submission history Latest submission status date: 2021-03-30 00:00:00.

Structured Monograph

Clinical summary

Approval overview CIPRO XR is listed in Drugs@FDA under application 021473 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE Form and strength TABLET, EXTENDED RELEASE;ORAL - 425.2MG;EQ 574.9MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor BAYER HLTHCARE Submission history Latest submission status date: 2021-03-30 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.